Insilico Medicine, a Hong Kong-based firm that uses artificial intelligence (AI) for drug discovery and ageing research, announced on Tuesday that it has raked in $255 million in a Series C round of financing led by US private equity (PE) giant Warburg Pincus.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
